G1 Therapeutics IncNASDAQ:GTHX
- LAST PRICE3.3000
- TODAY'S CHANGE (%)-0.0100 (-0.3021%)
- Bid / Lots3.3500/ 5
- Ask / Lots3.3900/ 5
- Open / Previous Close3.3300 / 3.3100
- Day Range
- 52 Week Range
- Volume677,169
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GTHX |
|---|---|---|
| 09:32 ET | 10612 | 3.35 |
| 09:34 ET | 15900 | 3.32 |
| 09:36 ET | 27657 | 3.33 |
| 09:38 ET | 9544 | 3.33 |
| 09:39 ET | 27264 | 3.38 |
| 09:41 ET | 23529 | 3.4301 |
| 09:43 ET | 5857 | 3.4438 |
| 09:45 ET | 3556 | 3.44 |
| 09:48 ET | 300 | 3.42 |
| 09:50 ET | 2016 | 3.41 |
| 09:52 ET | 7305 | 3.3908 |
| 09:54 ET | 500 | 3.375 |
| 09:56 ET | 7482 | 3.375 |
| 09:57 ET | 900 | 3.3501 |
| 09:59 ET | 1560 | 3.36 |
| 10:01 ET | 1660 | 3.3401 |
| 10:03 ET | 7378 | 3.335 |
| 10:06 ET | 600 | 3.335 |
| 10:08 ET | 627 | 3.34 |
| 10:10 ET | 500 | 3.34 |
| 10:12 ET | 866 | 3.335 |
| 10:14 ET | 200 | 3.34 |
| 10:15 ET | 2659 | 3.35 |
| 10:17 ET | 2319 | 3.355 |
| 10:19 ET | 1100 | 3.355 |
| 10:21 ET | 6072 | 3.345 |
| 10:24 ET | 1100 | 3.34 |
| 10:26 ET | 1635 | 3.33 |
| 10:28 ET | 413 | 3.325 |
| 10:30 ET | 600 | 3.325 |
| 10:32 ET | 4749 | 3.3103 |
| 10:33 ET | 100 | 3.31 |
| 10:35 ET | 5399 | 3.29 |
| 10:37 ET | 15117 | 3.28 |
| 10:39 ET | 3993 | 3.3 |
| 10:42 ET | 3669 | 3.305 |
| 10:44 ET | 100 | 3.31 |
| 10:48 ET | 321 | 3.3 |
| 10:50 ET | 100 | 3.29 |
| 10:51 ET | 206 | 3.29 |
| 10:53 ET | 100 | 3.3 |
| 10:55 ET | 2700 | 3.295 |
| 10:57 ET | 5905 | 3.275 |
| 11:00 ET | 7744 | 3.2703 |
| 11:02 ET | 1395 | 3.275 |
| 11:04 ET | 3000 | 3.2551 |
| 11:06 ET | 300 | 3.26 |
| 11:09 ET | 2117 | 3.27 |
| 11:11 ET | 1116 | 3.27 |
| 11:13 ET | 2370 | 3.26 |
| 11:15 ET | 600 | 3.27 |
| 11:18 ET | 100 | 3.28 |
| 11:22 ET | 100 | 3.275 |
| 11:24 ET | 100 | 3.275 |
| 11:26 ET | 4249 | 3.285 |
| 11:29 ET | 700 | 3.275 |
| 11:31 ET | 2512 | 3.28 |
| 11:33 ET | 602 | 3.28 |
| 11:36 ET | 100 | 3.28 |
| 11:38 ET | 100 | 3.27 |
| 11:40 ET | 2489 | 3.275 |
| 11:42 ET | 100 | 3.275 |
| 11:44 ET | 3232 | 3.295 |
| 11:47 ET | 300 | 3.3 |
| 11:49 ET | 4057 | 3.3 |
| 11:54 ET | 100 | 3.295 |
| 11:56 ET | 8642 | 3.32 |
| 12:00 ET | 21698 | 3.3 |
| 12:03 ET | 2707 | 3.3 |
| 12:07 ET | 100 | 3.295 |
| 12:09 ET | 100 | 3.295 |
| 12:12 ET | 783 | 3.295 |
| 12:14 ET | 1355 | 3.285 |
| 12:16 ET | 100 | 3.29 |
| 12:18 ET | 300 | 3.285 |
| 12:21 ET | 1336 | 3.285 |
| 12:23 ET | 734 | 3.2801 |
| 12:25 ET | 17293 | 3.29 |
| 12:27 ET | 100 | 3.285 |
| 12:30 ET | 100 | 3.285 |
| 12:32 ET | 900 | 3.285 |
| 12:34 ET | 3288 | 3.2901 |
| 12:36 ET | 300 | 3.3 |
| 12:38 ET | 3350 | 3.3 |
| 12:39 ET | 3239 | 3.3 |
| 12:41 ET | 300 | 3.3 |
| 12:43 ET | 300 | 3.3 |
| 12:45 ET | 700 | 3.3 |
| 12:50 ET | 300 | 3.3 |
| 12:54 ET | 1500 | 3.295 |
| 12:56 ET | 1416 | 3.3 |
| 12:59 ET | 100 | 3.305 |
| 01:01 ET | 100 | 3.31 |
| 01:03 ET | 8068 | 3.305 |
| 01:06 ET | 1700 | 3.3 |
| 01:08 ET | 100 | 3.3 |
| 01:10 ET | 300 | 3.3 |
| 01:12 ET | 2589 | 3.3 |
| 01:14 ET | 739 | 3.29 |
| 01:15 ET | 300 | 3.29 |
| 01:17 ET | 2851 | 3.28 |
| 01:19 ET | 3194 | 3.29 |
| 01:21 ET | 363 | 3.29 |
| 01:28 ET | 2194 | 3.29 |
| 01:30 ET | 17718 | 3.31 |
| 01:32 ET | 200 | 3.31 |
| 01:35 ET | 200 | 3.31 |
| 01:37 ET | 400 | 3.31 |
| 01:39 ET | 300 | 3.305 |
| 01:42 ET | 2106 | 3.295 |
| 01:44 ET | 200 | 3.295 |
| 01:46 ET | 200 | 3.295 |
| 01:48 ET | 1100 | 3.295 |
| 01:50 ET | 3250 | 3.295 |
| 01:51 ET | 500 | 3.29 |
| 01:53 ET | 4656 | 3.285 |
| 01:55 ET | 635 | 3.285 |
| 01:57 ET | 200 | 3.28 |
| 02:00 ET | 1700 | 3.285 |
| 02:02 ET | 3014 | 3.28 |
| 02:04 ET | 200 | 3.275 |
| 02:06 ET | 4846 | 3.265 |
| 02:08 ET | 738 | 3.26 |
| 02:09 ET | 300 | 3.265 |
| 02:11 ET | 4557 | 3.281 |
| 02:13 ET | 200 | 3.285 |
| 02:15 ET | 100 | 3.28 |
| 02:18 ET | 200 | 3.285 |
| 02:20 ET | 3207 | 3.295 |
| 02:22 ET | 300 | 3.3 |
| 02:24 ET | 100 | 3.3 |
| 02:26 ET | 500 | 3.2901 |
| 02:27 ET | 4023 | 3.295 |
| 02:29 ET | 200 | 3.3 |
| 02:31 ET | 600 | 3.295 |
| 02:33 ET | 500 | 3.3 |
| 02:36 ET | 345 | 3.295 |
| 02:38 ET | 200 | 3.3 |
| 02:40 ET | 3056 | 3.3 |
| 02:42 ET | 650 | 3.3 |
| 02:44 ET | 500 | 3.295 |
| 02:47 ET | 741 | 3.295 |
| 02:49 ET | 3081 | 3.29 |
| 02:54 ET | 437 | 3.29 |
| 02:56 ET | 626 | 3.29 |
| 02:58 ET | 14920 | 3.29 |
| 03:00 ET | 100 | 3.285 |
| 03:02 ET | 2109 | 3.2814 |
| 03:03 ET | 4035 | 3.28 |
| 03:05 ET | 100 | 3.28 |
| 03:07 ET | 2236 | 3.2752 |
| 03:09 ET | 200 | 3.285 |
| 03:12 ET | 428 | 3.29 |
| 03:14 ET | 180 | 3.285 |
| 03:16 ET | 3133 | 3.285 |
| 03:18 ET | 6710 | 3.278 |
| 03:20 ET | 719 | 3.275 |
| 03:21 ET | 700 | 3.275 |
| 03:23 ET | 1378 | 3.275 |
| 03:25 ET | 381 | 3.275 |
| 03:27 ET | 300 | 3.27 |
| 03:30 ET | 1400 | 3.275 |
| 03:32 ET | 13013 | 3.265 |
| 03:34 ET | 1648 | 3.265 |
| 03:36 ET | 11410 | 3.265 |
| 03:38 ET | 1599 | 3.26 |
| 03:39 ET | 1490 | 3.26 |
| 03:41 ET | 10782 | 3.275 |
| 03:43 ET | 1900 | 3.28 |
| 03:45 ET | 16458 | 3.295 |
| 03:48 ET | 6402 | 3.305 |
| 03:50 ET | 1800 | 3.305 |
| 03:52 ET | 6805 | 3.3099 |
| 03:54 ET | 8138 | 3.3 |
| 03:56 ET | 8212 | 3.2973 |
| 03:57 ET | 1837 | 3.295 |
| 03:59 ET | 10021 | 3.3 |
May 28, 2024
DJ G1 Therapeutics Price Target Maintained With a $9.00/Share by HC Wainwright & Co., from 12:42PM ET on Tuesday May 28, 2024 by Dow Jones
12:42PM ET on Tuesday May 28, 2024 by Dow JonesDJ G1 Therapeutics Price Target Maintained With a $12.00/Share by Needham, from 11:13AM ET on Tuesday May 28, 2024 by Dow Jones
11:13AM ET on Tuesday May 28, 2024 by Dow JonesMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC), from 6:30AM ET on Tuesday May 28, 2024 by Dow Jones
6:30AM ET on Tuesday May 28, 2024 by Dow Jones
May 23, 2024
G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting, from 5:06PM ET on Thursday May 23, 2024 by Dow Jones
5:06PM ET on Thursday May 23, 2024 by Dow Jones
May 22, 2024
DJ G1 Therapeutics Price Target Maintained With a $12.00/Share by Needham, from 12:25PM ET on Wednesday May 22, 2024 by Dow Jones
12:25PM ET on Wednesday May 22, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
G1 Therapeutics Inc | 172.5M | -5.4x | --- |
Alimera Sciences Inc | 159.8M | -1.9x | --- |
Chromadex Corp | 208.5M | -58.7x | --- |
Enanta Pharmaceuticals Inc | 264.1M | -2.0x | --- |
Codexis Inc | 238.5M | -3.6x | --- |
Fortress Biotech Inc | 36.6M | -0.3x | --- |
Company Information
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of small molecule therapeutics for the treatment of patients with cancer. The Company's lead commercial product, COSELA (trilaciclib), is a therapy indicated to proactively help protect bone marrow (myeloprotection) from the damage of chemotherapy. Its product portfolio consists of Trilaciclib and Lerociclib, both of which are CDK4/6 inhibitors, and a Cyclin-dependent kinase 2 (CDK2) inhibitor. Trilaciclib is a novel therapy designed to transiently arrest cells that are dependent on CDK4/6 for proliferation, including hematopoietic stem and progenitor cells (HSPCs), in the G1 phase. Lerociclib is a differentiated clinical-stage oral CDK4/6 inhibitor being developed for use in combination with other targeted therapies in multiple oncology indications. COSELA is a short-acting intravenous CDK4/6 inhibitor. Its CDK2 is an internally discovered inhibitor.
Contact Information
- Headquarters
- 700 Park Offices Drive, Suite 200RESEARCH TRIANGLE PARK, NC, United States 27709
- Phone
- 919-213-9835
- Fax
- 919-741-5830
Executives
- Independent Chairman of the Board
- Garry Nicholson
- President, Chief Executive Officer, Director
- John Bailey
- Chief Financial Officer
- John V
- Chief Operating Officer
- Terry Murdock
- Chief Compliance Officer, General Counsel
- Monica Thomas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $172.5M |
|---|---|
Revenue (TTM) | $84.0M |
Shares Outstanding | 52.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.71 |
EPS | $-0.61 |
Book Value | $0.68 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | 2.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -27.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
